Testing effectiveness (Phase 2)Ended earlyNCT02154529
What this trial is testing
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Who this might be right for
HER-2 Positive Breast CancerMetastatic Malignant Neoplasm to Brain
Kadmon Corporation, LLC 17